September 9, 2020


Merck introduces combination intranasal vaccine for cattle


Merck has introduced Nasalgen® 3-PMH, the only intranasal vaccine that protects beef and dairy cattle from the five most common pneumonia-causing viral and bacterial pathogens, Bovine Veterinarian reported.

The vaccine provides early, broad-spectrum respiratory protection in a needle free, animal- and BQA (Beef Quality Assurance)-friendly administration.

"Nasalgen 3-PMH is a modified-live, intranasal vaccine that stimulates a strong early immune response to help give calves a strong foundation of respiratory disease protection," says Scott Nordstrom, D.V.M., director of livestock innovation and discovery, Merck Animal Health. "Results of efficacy, duration of immunity and safety studies demonstrate the vaccine is safe and effective for calves at one week of age or older."

The combination vaccines provides six-and-a-half-month duration of immunity (DOI) against infectious bovine rhinotracheitis (IBR), an 11-week DOI against bovine respiratory syncytial virus (BRSV), three-month DOI against parainfluenza 3 (PI3), as well as a four-month DOI against Mannheimia haemolytica and Pasteurella multocida.

When young calves are vaccinated, maternal antibodies from colostrum can affect the vaccine's effectiveness. Nasalgen intranasal vaccines are said to be unique as they are delivered to mucosal surfaces in the nose - an area loaded with immunologically active tissues - to avoid interference from maternal antibodies.

The introduction of Nasalgen 3-PMH comes after the launch of Nasalgen 3 earlier this year. Both vaccines are designed with an IBR and PI3 that are not temperature-sensitive, enabling protection in a moderate to high temperature environment.

Nasalgen 3-PMH will be available for purchase in early 2021. Interested parties are advised to consult their veterinarians for specific usage guidance.